

2019 Dermatology Managers Association Conference

Measure Title	NQF	Quality Number (Q#)	Measure Description	Measure Type	High Priority	Collection Type(s)					
						MCR Part B Claims	CSV	eCQM	CMS Web Interface	Administrative	MIPS CQM
Documentation of Current Medications in the Medical Record	0419	130	Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration	Process	X	X	-	X	-	-	X
Melanoma: Continuity of Care – Recall System	N/A	137	Percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within a 12 month period, into a recall system that includes: <ul style="list-style-type: none"> • A target date for the next complete physical skin exam, AND • A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment 	Structure	X	-	-	-	-	-	X
Melanoma: Coordination of Care	N/A	138	Percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis	Process	X	-	-	-	-	-	X
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	0028	226	Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received tobacco cessation intervention if identified as a tobacco user	Process	-	X	-	X	X	-	X

2019 Dermatology Managers Association Conference

Biopsy Follow-Up	N/A	265	Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient	Process	X	-	-	-	-	-	X
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	N/A	317	Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated	Process	-	X	-	X	-	-	X
Closing the Referral Loop: Receipt of Specialist Report	N/A	374	Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred	Process	X	-	-	X	-	-	X
Tobacco Use and Help with Quitting Among Adolescents	N/A	402	The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user	Process	-	-	-	-	-	-	X
Psoriasis: Clinical Response to Systemic Medications	N/A	410	Percentage of psoriasis vulgaris patients receiving systemic therapy who meet minimal physician-or patient-reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment	Outcome	X	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time – Pathologist to Clinician	N/A	440	Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) (including in situ disease) in which the pathologist communicates results to the clinician within 7 days from the time when the tissue specimen was received by the pathologist	Process	X	-	-	-	-	-	X
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	0004	305	Percentage of patients 13 years of age and older with a new episode of alcohol and other drug (AOD) dependence who received the following. Two rates are reported. a. Percentage of patients who initiated treatment within 14 days of the diagnosis b. Percentage of patients who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit	Process	-	-	-	X	-	-	-
Cervical Cancer Screening	0032	309	Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria: * Women age 21-64 who had cervical cytology performed every 3 years * Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years	Process	-	-	-	X	-	-	-
Falls: Screening for Future Fall Risk	0101	318	Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period	Process	X	-	-	X	X	-	-

2019 Dermatology Managers Association Conference

CAHPS for MIPS Clinician/Group Survey	0005 & 0006	321	<p>The Consumer Assessment of Healthcare Providers and Systems (CAHPS) for MIPS Clinician/Group Survey is comprised of 10 Summary Survey Measures (SSMs) and measures patient experience of care within a group practice. The NQF endorsement status and endorsement id (if applicable) for each SSM utilized in this measure are as follows:</p> <ul style="list-style-type: none"> • Getting timely care, appointments, and information; • How well providers Communicate; • Patient’s Rating of Provider; • Access to Specialists; • Health Promotion & Education; • Shared Decision Making; • Health Status/Functional Status; • Courteous and Helpful Office Staff; • Care Coordination; and • Stewardship of Patient Resources 	Patient Engagement/Experience	X	-	X	-	-	-	-
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	1525	326	Percentage of patients aged 18 years and older with nonvalvular atrial fibrillation (AF) or atrial flutter who were prescribed warfarin OR another FDA-approved oral anticoagulant drug for the prevention of thromboembolism during the measurement period	Process	-	X	-	-	-	-	X
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)	N/A	331	Percentage of patients, aged 18 years and older, with a diagnosis of acute viral sinusitis who were prescribed an antibiotic within 10 days after onset of symptoms	Process	X	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)	N/A	332	Percentage of patients aged 18 years and older with a diagnosis of acute bacterial sinusitis that were prescribed amoxicillin, with or without clavulanate, as a first line antibiotic at the time of diagnosis	Process	X	-	-	-	-	-	X
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)	N/A	333	Percentage of patients aged 18 years and older, with a diagnosis of acute sinusitis who had a computerized tomography (CT) scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis	Efficiency	X	-	-	-	-	-	X
Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological	N/A	337	Percentage of patients, regardless of age, with psoriasis, psoriatic arthritis and rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient's history to determine if they have had appropriate management for a recent or prior positive test	Process	-	-	-	-	-	-	X
HIV Viral Load Suppression	2082	338	The percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year	Outcome	X	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

Pain Brought Under Control Within 48 Hours	N/A	342	Patients aged 18 and older who report being uncomfortable because of pain at the initial assessment (after admission to palliative care services) who report pain was brought to a comfortable level within 48 hours	Outcome	X	-	-	-	-	-	X
Depression Remission at Twelve Months	0710	370	The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event	Outcome	X	-	-	X	X	-	X
Depression Utilization of the PHQ-9 Tool	N/A	371	The percentage of adolescent patients 12 to 17 years of age and adult patients age 18 and older with the diagnosis of major depression or dysthymia who have a completed PHQ-9 during each applicable 4 month period in which there was a qualifying depression encounter	Process	-	-	-	X	-	-	-
Closing the Referral Loop: Receipt of Specialist Report	N/A	374	Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred	Process	X	-	-	X	-	-	X
Functional Status Assessments for Congestive Heart Failure	N/A	377	Percentage of patients 18 years of age and older with congestive heart failure who completed initial and follow-up patient-reported functional status assessments	Process	X	-	-	X	-	-	-
Adherence to Antipsychotic Medications For Individuals with Schizophrenia	1879	383	Percentage of individuals at least 18 years of age as of the beginning of the measurement period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the measurement period (12 consecutive months)	Intermediate Outcome	X	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users	N/A	387	Percentage of patients, regardless of age, who are active injection drug users who received screening for HCV infection within the 12-month reporting period	Process	-	-	-	-	-	-	-	X
Optimal Asthma Control	N/A	398	Composite measure of the percentage of pediatric and adult patients whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools and not at risk for exacerbation	Outcome	X	-	-	-	-	-	-	X
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	3059	400	Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis, OR birthdate in the years 1945-1965 who received one-time screening for hepatitis C virus (HCV) infection	Process	-	-	-	-	-	-	-	X
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis	N/A	401	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month submission period	Process	-	-	-	-	-	-	-	X
Tobacco Use and Help with Quitting Among Adolescents	N/A	402	The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user	Process	-	-	-	-	-	-	-	X
Opioid Therapy Follow-up Evaluation	N/A	408	All patients 18 and older prescribed opiates for longer than six weeks duration who had a follow-up evaluation conducted at least every three months during Opioid Therapy documented in the medical record	Process	X	-	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

Documentation of Signed Opioid Treatment Agreement	N/A	412	All patients 18 and older prescribed opiates for longer than six weeks duration who signed an opioid treatment agreement at least once during Opioid Therapy documented in the medical record	Process	X	-	-	-	-	-	X
Evaluation or Interview for Risk of Opioid Misuse	N/A	414	All patients 18 and older prescribed opiates for longer than six weeks duration evaluated for risk of opioid misuse using a brief validated instrument (e.g. Opioid Risk Tool, SOAPP-R) or patient interview documented at least once during Opioid Therapy in the medical record	Process	X	-	-	-	-	-	X
Osteoporosis Management in Women Who Had a Fracture	0053	418	The percentage of women age 50-85 who suffered a fracture in the six months prior to the performance period through June 30 of the performance period and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture	Process	-	X	-	-	-	-	X
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling	2152	431	Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol user	Process	-	-	-	-	-	-	X

2019 Dermatology Managers Association Conference

<p style="text-align: center;">Statin Therapy for the Prevention and Treatment of Cardiovascular Disease</p>	<p style="text-align: center;">N/A</p>	<p style="text-align: center;">438</p>	<p>Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *Adults aged >= 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR *Adults aged >= 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level >= 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR *Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL</p>	<p style="text-align: center;">Process</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">X</p>	<p style="text-align: center;">X</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">X</p>
<p style="text-align: center;">Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)</p>	<p style="text-align: center;">N/A</p>	<p style="text-align: center;">441</p>	<p>The IVD All-or-None Measure is one outcome measure (optimal control). The measure contains four goals. All four goals within a measure must be reached in order to meet that measure. The numerator for the all-or-none measure should be collected from the organization's total IVD denominator. All-or-None Outcome Measure (Optimal Control) - Using the IVD denominator optimal results include: • <u>Most recent blood pressure (BP) measurement is less</u></p>	<p style="text-align: center;">Intermedi ate Outcome</p>	<p style="text-align: center;">X</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">X</p>
<p style="text-align: center;">Persistence of Beta-Blocker Treatment After a Heart Attack</p>	<p style="text-align: center;">0071</p>	<p style="text-align: center;">442</p>	<p>The percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who were prescribed persistent beta-blocker treatment for six months after discharge</p>	<p style="text-align: center;">Process</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">-</p>	<p style="text-align: center;">X</p>

2019 Dermatology Managers Association Conference

Non-Recommended Cervical Cancer Screening in Adolescent Females	N/A	443	The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer	Process	X	-	-	-	-	-	X
Medication Management for People with Asthma	N/A	444	The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period	Process	X	-	-	-	-	-	X
Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)	3175	468	Percentage of adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment	Process	X	-	-	-	-	-	X
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture	N/A	472	Percentage of female patients 50 to 64 years of age without select risk factors for osteoporotic fracture who received an order for a dual-energy x-ray absorptiometry (DXA) scan during the measurement period.	Process	X	-	-	X	-	-	-
Zoster (Shingles) Vaccination	N/A	474	The percentage of patients aged 50 years and older who have had a Varicella Zoster (shingles) vaccination.	Process	-	-	-	-	-	-	X
HIV Screening	N/A	475	Percentage of patients 15-65 years of age who have been tested for human immunodeficiency virus (HIV).	Process	-	-	-	X	-	-	-